Oscar Health, Inc. (NYSE:OSCR) Shares Purchased by US Bancorp DE

US Bancorp DE grew its stake in shares of Oscar Health, Inc. (NYSE:OSCR) by 115.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,784 shares of the company’s stock after purchasing an additional 13,305 shares during the quarter. US Bancorp DE’s holdings in Oscar Health were worth $526,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Oscar Health by 2.4% in the first quarter. Vanguard Group Inc. now owns 14,582,762 shares of the company’s stock worth $216,846,000 after purchasing an additional 337,850 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Oscar Health by 153.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,978,152 shares of the company’s stock valued at $59,156,000 after acquiring an additional 2,409,160 shares during the period. Renaissance Technologies LLC raised its position in shares of Oscar Health by 31.7% during the second quarter. Renaissance Technologies LLC now owns 3,886,100 shares of the company’s stock valued at $61,478,000 after buying an additional 934,600 shares during the last quarter. First Light Asset Management LLC raised its position in Oscar Health by 117.3% in the first quarter. First Light Asset Management LLC now owns 2,102,554 shares of the company’s stock worth $31,265,000 after purchasing an additional 1,134,919 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its position in Oscar Health by 32.9% in the second quarter. Assenagon Asset Management S.A. now owns 2,046,046 shares of the company’s stock worth $32,368,000 after purchasing an additional 507,009 shares in the last quarter. Institutional investors and hedge funds own 75.70% of the company’s stock.

Oscar Health Stock Performance

NYSE OSCR opened at $13.80 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.91 and a current ratio of 0.91. The company has a market capitalization of $3.34 billion, a PE ratio of -230.00, a price-to-earnings-growth ratio of 31.17 and a beta of 1.67. Oscar Health, Inc. has a 52-week low of $6.80 and a 52-week high of $23.79. The company has a 50-day simple moving average of $18.45 and a 200 day simple moving average of $18.36.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Oscar Health had a net margin of 0.35% and a return on equity of 2.91%. The firm had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.33 billion. During the same period in the previous year, the business earned ($0.29) earnings per share. The firm’s revenue for the quarter was up 68.3% on a year-over-year basis. On average, research analysts predict that Oscar Health, Inc. will post 0.02 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on OSCR. Bank of America cut shares of Oscar Health from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $21.00 to $13.50 in a research note on Wednesday, November 6th. UBS Group assumed coverage on shares of Oscar Health in a research report on Monday, October 7th. They issued a “neutral” rating and a $23.00 target price for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of Oscar Health in a research note on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Oscar Health currently has a consensus rating of “Moderate Buy” and an average price target of $22.93.

Insider Buying and Selling

In related news, EVP Alessandrea C. Quane sold 16,793 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $17.06, for a total transaction of $286,488.58. Following the transaction, the executive vice president now owns 392,607 shares in the company, valued at $6,697,875.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Mario Schlosser sold 3,198 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $17.99, for a total transaction of $57,532.02. Following the completion of the transaction, the insider now directly owns 76,982 shares of the company’s stock, valued at $1,384,906.18. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Alessandrea C. Quane sold 16,793 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $17.06, for a total transaction of $286,488.58. Following the sale, the executive vice president now directly owns 392,607 shares of the company’s stock, valued at approximately $6,697,875.42. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 169,569 shares of company stock worth $3,007,069 in the last 90 days. 25.11% of the stock is owned by company insiders.

Oscar Health Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.